Edition:
United States

Mesoblast Ltd (MSB.AX)

MSB.AX on Australia Stock Exchange

1.62AUD
11:18pm EST
Change (% chg)

$-0.01 (-0.91%)
Prev Close
$1.64
Open
$1.63
Day's High
$1.71
Day's Low
$1.61
Volume
553,635
Avg. Vol
706,402
52-wk High
$3.03
52-wk Low
$1.01

Select another date:

Mon, Nov 14 2016

BRIEF-Mesoblast qtrly loss per share 5.24 cents

* Mesoblast provides corporate update and financial results for the first quarter ended September 30, 2016 Source text for Eikon: Further company coverage:

BRIEF-Mesoblast names Bill Burns as vice chairman

* Mesoblast appoints Bill Burns, former chief executive of Roche Pharmaceuticals, as vice chairman Source text for Eikon: Further company coverage:

BRIEF-Mesoblast reports Q4 earnings per share $0.1278

* Mesoblast reports financial results and operational highlights for the three months and for the year ended 30 june 2016

BRIEF-Mesoblast intends to enter into strategic partnership advancing phase 3 development of allogeneic MPCS for biologic Refractory RA

* Phase 2 trial of mesoblast cell therapy shows dose-related clinical benefit in patients with biologic refractory rheumatoid arthritis

Mesoblast cell treatment shows promise in rheumatoid arthritis : study

Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

Mesoblast cell treatment shows promise in rheumatoid arthritis -study

Aug 8 Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines, according to data from a mid-stage trial.

Select another date: